Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
— Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to be presented in an oral session — — Additional poster presentations to include debut of web-based tool for identifying geographical areas across the country in … [Read more…]